Overall, these data underscore that activation of CD8+ OT-1 T cells by DCs treated with SIINFEKL-loaded 90/10-CNPs leads to antigen-specific expansion of CD8+ T cells and antigen-specific, efficient tumor cell killing. This evidence concerns the gene CD8A and neoplasm.